L. Seeff

Hepatology · 2000–2011

A researcher in the Science corpus: 8 papers; trusts 1 researcher and is trusted by 9 researchers here, as inferred from the citation graph.

Subfields

Whom L. Seeff trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. Hoofnagle

Who trusts L. Seeff overall

  1. Peter Simmonds
  2. J. Hoofnagle
  3. B. Rehermann
  4. Stephen L. Chen
  5. J. Ladero
  6. Jordi Bruix1 , 2

Papers from L. Seeff's perspective

Ordered by how strongly the researchers L. Seeff trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Telaprevir for retreatment of HCV infection. (New England Journal of Medicine)
  2. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy (Nature Genetics)
  3. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. (Gastroenterology)
  4. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus (Nature)
  5. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an… (The Lancet)
  6. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. (Gastroenterology)
  7. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance (Nature)
  8. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. (Journal of Hepatology)
  9. Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus (Journal of Experimental Medicine)
  10. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. (Journal of the American Medical Association (JAMA))

Their papers